期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 104, 期 3, 页码 534-538出版社
WILEY
DOI: 10.1002/cpt.981
关键词
-
资金
- Health Systems Research and Development Project (Faculty of Medicine Siriraj Hospital, Thailand)
- Thai Health Promotion Fund
- Health Systems Research Institute (Thailand)
- Government Pharmaceutical Organization (Thailand)
- Singapore Ministry of Health Communicable Diseases Public Health Research Grant [CDPHRG/12NOV015]
- Singapore National Medical Research Council Clinician Scientist Award [NMRC/CSAINV/0005/2016]
Polymyxin B is used as a last treatment resort for multidrug-resistant Gram-negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability. Four serial blood samples each were collected from 35 adult patients at steady state. The concentrations of individual polymyxin B components were analyzed using a validated liquid chromatography / tandem mass spectrometry assay and combined to derive total concentrations. A maximum likelihood expectation maximization approach was used to fit the data. Various demographic variables were investigated as potential covariates for clearance and volume of distribution (V-d) using linear regression analysis. A one-compartment model fit to the data satisfactorily (r(2)=0.96). The best-fit mean +/- SD for clearance and V-d were 2.5 +/- 1.1L/h and 34.3 +/- 16.4L, respectively. Creatinine clearance was found to be a statistically significant covariate of clearance, but the magnitude was deemed clinically insignificant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据